Galapagos NV (GLPG) Now Covered by Analysts at Royal Bank Of Canada

Equities researchers at Royal Bank Of Canada began coverage on shares of Galapagos NV (NASDAQ:GLPG) in a report released on Thursday. The firm set a “sector perform” rating on the biotechnology company’s stock.

GLPG has been the subject of a number of other research reports. Stifel Nicolaus upgraded Galapagos NV from a “hold” rating to a “buy” rating and lifted their price objective for the company from $83.00 to $101.00 in a research note on Friday, August 11th. Zacks Investment Research upgraded Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price objective for the company in a research note on Friday, July 14th. TheStreet upgraded Galapagos NV from a “d+” rating to a “c” rating in a research note on Wednesday, May 17th. BTIG Research reiterated a “buy” rating and set a $98.00 price objective on shares of Galapagos NV in a research note on Tuesday, June 20th. Finally, BidaskClub upgraded Galapagos NV from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $101.50.

Shares of Galapagos NV (GLPG) traded up 1.96% during mid-day trading on Thursday, reaching $103.46. The company’s stock had a trading volume of 70,350 shares. Galapagos NV has a 12-month low of $57.16 and a 12-month high of $103.54. The firm’s 50-day moving average price is $101.59 and its 200 day moving average price is $84.97.

ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/09/14/galapagos-nv-glpg-now-covered-by-analysts-at-royal-bank-of-canada.html.

Several institutional investors have recently made changes to their positions in the stock. Cookson Peirce & Co. Inc. increased its stake in shares of Galapagos NV by 0.7% in the 2nd quarter. Cookson Peirce & Co. Inc. now owns 3,045 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 20 shares in the last quarter. Macquarie Group Ltd. increased its stake in shares of Galapagos NV by 1.7% in the 2nd quarter. Macquarie Group Ltd. now owns 9,238 shares of the biotechnology company’s stock valued at $707,000 after purchasing an additional 156 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Galapagos NV by 0.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 38,093 shares of the biotechnology company’s stock valued at $2,915,000 after purchasing an additional 173 shares in the last quarter. Northern Trust Corp increased its stake in shares of Galapagos NV by 2.9% in the 2nd quarter. Northern Trust Corp now owns 18,480 shares of the biotechnology company’s stock valued at $1,414,000 after purchasing an additional 524 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Galapagos NV by 18.8% in the 1st quarter. Bank of America Corp DE now owns 4,379 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 694 shares in the last quarter. Hedge funds and other institutional investors own 23.63% of the company’s stock.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply